Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Prototype Developer (U18 Clinical Trial Not Allowed)
ID: 333893Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint MedTech: Prototype Developer program, aimed at supporting the development of human-grade medical device prototypes. This initiative will facilitate projects that encompass product definition and development activities, including needs assessment, product design, prototype development, and bench testing, ultimately preparing for first-in-human testing through subsequent FOAs. The FOA is expected to be published in Summer 2021, with applications due in Fall 2021, and interested applicants can reach out to Michael Wolfson, Ph.D., at Blueprint-MedTech@nih.gov or by phone at 301-451-6987 for further information. There is no cost-sharing or matching requirement for this cooperative agreement, and the opportunity is categorized as discretionary funding for eligible applicants.

    Point(s) of Contact
    Files
    No associated files provided.
    Similar Opportunities
    Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition – Medical Device Prototype Optimization" (RFA-HL-26-020) aimed at supporting early-stage translational research for the optimization of prototypes related to heart, lung, blood, and sleep (HLBS) diseases. This initiative seeks to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates, encouraging significant improvements over existing solutions through strong biological rationale and preliminary data. The total anticipated funding is approximately $4.466 million per fiscal year from FY 2026 to FY 2028, with applications due by 5 PM local time on specified dates, and a maximum project duration of two years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity titled "Catalyze Product Definition," aimed at supporting the development of medical device prototypes, diagnostic targets, and related research tools for heart, lung, blood, and sleep (HLBS) diseases. This initiative adopts a phased approach (R61/R33) to assist early-stage projects, focusing on preliminary prototype testing in the R61 phase and advancing to extensive development activities in the R33 phase, with a requirement for applicants to demonstrate novelty and a strong biological rationale supported by preliminary data. The program anticipates funding approximately $4.4 million annually from FY 2026 to FY 2028, with up to 24 awards available, and requires applicants to engage with an Accelerator Partner to enhance commercialization expertise. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline of December 23, 2027.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed) aimed at fostering collaborations between academic and industrial organizations to develop innovative biomedical solutions. This initiative encourages the establishment of robust engineering solutions to address significant biomedical challenges, requiring applicants to form strategic alliances and outline a detailed plan with specific milestones to achieve results within 5-10 years. The anticipated funding opportunity announcement is expected to be published in February 2022, with applications due by May 2022, and the estimated award date is set for April 1, 2023. For further inquiries, interested parties can contact Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing innovative technologies in biomedical research. This initiative seeks applications that propose high-risk, high-reward projects focused on technology development without existing proof of concept, specifically excluding clinical trials. The funding amount is capped at $275,000 in direct costs over two years, with a maximum of $200,000 available in any single year. Interested applicants, including higher education institutions and nonprofit organizations, must adhere to submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is January 7, 2028.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), aimed at advancing biologic-based drug discovery and development for disorders of the nervous system. This initiative seeks applications from researchers focused on developing a variety of biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, specifically targeting nervous system and neuromuscular disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the UG3/UH3 activity code. Interested applicants should prepare for collaboration opportunities, as the estimated award date is set for December 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), focusing on biologic-based drug discovery and development for disorders of the nervous system. This initiative aims to solicit applications from researchers working on diverse biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, to address various nervous system disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the U44 activity code. Interested applicants should prepare for collaboration and project development, as the estimated award date is set for December 1, 2025. For further details, potential applicants can refer to the NIH website or contact the agency directly.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This funding opportunity supports projects through two phases: R61 for non-clinical activities and R33 for small clinical studies, with a focus on ensuring compliance with Environmental Health and Safety regulations. The program emphasizes diversity in applicant teams and requires a Plan for Enhancing Diverse Perspectives, with key deadlines including submission openings starting December 28, 2024, and a close date of January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Notice of Funding Opportunity for National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a Notice of Funding Opportunity (NOFO) for the National Centers for Biomedical Imaging and Bioengineering (NCBIB), with a focus on advancing research in biomedical imaging and bioengineering. This grant opportunity, identified as P41 Clinical Trials Optional, aims to foster meaningful collaborations and innovative projects within the research community. The anticipated funding amount for this initiative is up to $750,000, with the NOFO expected to be published in late summer 2023 and applications due in fall 2023. Interested applicants should prepare for the estimated project start date of July 30, 2024, and can expect the award announcement by June 30, 2024.